Prosight Management, LP reported 32 positions worth $515.48M for the quarter ended Sep 30, 2026, down 9.0% on the prior quarter. It opened 9 new positions, added to 11, trimmed 12 and exited 12. Its largest holding is Lakefront Biotherapeutics NV at 11.5% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ABVX Abivax S.A. | +269.4K | +250.9% | $26.68M | 7.24% |
| PRVA Privia Health Group, Inc. | +1.05M | – | $20.67M | 4.01% |
| STTK Shattuck Labs, Inc. | +1.69M | +28.4% | $11.53M | 10.12% |
| DNLI Denali Therapeutics Inc. | +550.7K | – | $11.38M | 2.21% |
| PRAX Praxis Precision Medicines, Inc. | +36.4K | – | $10.60M | 2.06% |
| HQY Healthequity, Inc. | +115.8K | – | $10.24M | 1.99% |
| BBIO BridgeBio Pharma, Inc. | +150.0K | – | $9.87M | 1.91% |
| MLYS Mineralys Therapeutics, Inc. | +350.2K | +77.9% | $8.80M | 3.9% |
| HUM Humana Inc | +22.0K | – | $8.39M | 1.63% |
| ALKS Alkermes plc. | +155.6K | +39.5% | $6.31M | 4.32% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| BSX Boston Scientific Corp | -720.3K | -56.7% | $31.44M | 4.66% |
| VEEV Veeva Systems Inc | -106.2K | -100.0% | $18.85M | Exited |
| INSM INSMED Inc | -137.5K | -36.6% | $15.70M | 5.27% |
| ALNY Alnylam Pharmaceuticals, Inc. | -61.1K | -62.3% | $15.07M | 1.77% |
| JANX Janux Therapeutics, Inc. | -861.3K | -22.6% | $14.88M | 9.87% |
| ADCT ADC Therapeutics SA | -7.42M | -94.9% | $9.06M | 0.095% |
| KURA Kura Oncology, Inc. | -747.0K | -36.9% | $8.00M | 2.65% |
| ICUI Icu Medical Inc | -51.0K | -100.0% | $7.48M | Exited |
| SNDX Syndax Pharmaceuticals Inc | -387.4K | -32.3% | $7.28M | 2.96% |
| ISRG Intuitive Surgical Inc | -17.0K | -100.0% | $6.76M | Exited |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| PRVA Privia Health Group, Inc. | +1.05M | $20.67M | 4.01% |
| DNLI Denali Therapeutics Inc. | +550.7K | $11.38M | 2.21% |
| PRAX Praxis Precision Medicines, Inc. | +36.4K | $10.60M | 2.06% |
| HQY Healthequity, Inc. | +115.8K | $10.24M | 1.99% |
| BBIO BridgeBio Pharma, Inc. | +150.0K | $9.87M | 1.91% |
| HUM Humana Inc | +22.0K | $8.39M | 1.63% |
| ENOV Enovis CORP | +267.4K | $4.89M | 0.948% |
| QTRX Quanterix Corp | +825.0K | $3.06M | 0.594% |
| GENB Generate Biomedicines, Inc. | +144.8K | $2.17M | 0.422% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| VEEV Veeva Systems Inc | -106.2K | $18.85M | 3.33% |
| ICUI Icu Medical Inc | -51.0K | $7.48M | 1.32% |
| ISRG Intuitive Surgical Inc | -17.0K | $6.76M | 1.19% |
| PRCT PROCEPT BioRobotics Corp | -268.3K | $6.06M | 1.07% |
| WGS GeneDx Holdings Corp. | -85.5K | $5.87M | 1.04% |
| OPCH Option Care Health, Inc. | -270.7K | $5.68M | 1% |
| EBS Emergent BioSolutions Inc. | -460.0K | $3.85M | 0.681% |
| PFE Pfizer Inc | -135.4K | $3.26M | 0.576% |
| KIDS Orthopediatrics Corp | -157.5K | $3.01M | 0.532% |
| TECX Tectonic Therapeutic, Inc. | -39.7K | $1.37M | 0.241% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | LKFT Lakefront Biotherapeutics NV | Healthcare | 2.00M | $59.25M | 11.49% | -44.9K | -2.2% | Reduced | 3.03% |
| 2 | STTK Shattuck Labs, Inc. | Healthcare | 7.65M | $52.16M | 10.12% | +1.69M | +28.4% | Added | 4.17% |
| 3 | JANX Janux Therapeutics, Inc. | Healthcare | 2.94M | $50.86M | 9.87% | -861.3K | -22.6% | Reduced | 0.03% |
| 4 | NKTR Nektar Therapeutics | Healthcare | 785.0K | $47.53M | 9.22% | -25.0K | -3.1% | Reduced | 2.3% |
| 5 | ABVX Abivax S.A. | Healthcare | 376.8K | $37.31M | 7.24% | +269.4K | +250.9% | Added | 0.54% |
| 6 | INSM INSMED Inc | Healthcare | 238.1K | $27.18M | 5.27% | -137.5K | -36.6% | Reduced | 0% |
| 7 | BSX Boston Scientific Corp | Healthcare | 550.0K | $24.01M | 4.66% | -720.3K | -56.7% | Reduced | 0.04% |
| 8 | IRTC iRhythm Holdings, Inc. | Healthcare | 201.0K | $22.84M | 4.43% | +35.5K | +21.4% | Added | 0.61% |
| 9 | ALKS Alkermes plc. | Healthcare | 550.0K | $22.29M | 4.32% | +155.6K | +39.5% | Added | 0.3% |
| 10 | PRVA Privia Health Group, Inc. | Healthcare | 1.05M | $20.67M | 4.01% | +1.05M | – | New | 0.03% |
| 11 | MLYS Mineralys Therapeutics, Inc. | Healthcare | 800.0K | $20.10M | 3.9% | +350.2K | +77.9% | Added | 10.78% |
| 12 | ZYME Zymeworks Inc. | Healthcare | 721.1K | $19.10M | 3.71% | +46.7K | +6.9% | Added | 0.08% |
| 13 | SNDX Syndax Pharmaceuticals Inc | Healthcare | 812.6K | $15.28M | 2.96% | -387.4K | -32.3% | Reduced | 0.01% |
| 14 | KURA Kura Oncology, Inc. | Healthcare | 1.28M | $13.66M | 2.65% | -747.0K | -36.9% | Reduced | 1.42% |
| 15 | DNLI Denali Therapeutics Inc. | Healthcare | 550.7K | $11.38M | 2.21% | +550.7K | – | New | 0.29% |
Tip. Select a row to see that position’s full history at Prosight Management.
As of its Q3 2026 13F filing, Prosight Management, LP’s five largest positions were Lakefront Biotherapeutics NV (LKFT) at 11.5%, Shattuck Labs, Inc. (STTK) at 10.1%, Janux Therapeutics, Inc. (JANX) at 9.9%, Nektar Therapeutics (NKTR) at 9.2%, Abivax S.A. (ABVX) at 7.2% of the reported portfolio.
Prosight Management, LP reported a 13F portfolio worth $515.48M across 32 positions for Q3 2026. That is down 9.0% from the previous quarter.
Its largest purchases by value were Abivax S.A. ($26.68M), Privia Health Group, Inc. ($20.67M), Shattuck Labs, Inc. ($11.53M). It opened 9 new positions.
Its largest sales by value were Boston Scientific Corp ($31.44M), Veeva Systems Inc ($18.85M), INSMED Inc ($15.70M). It exited 12 positions entirely.
From the Form 13F-HR reports Prosight Management, LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.